Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia-Reference-Cited by-同舟云学术

Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia

Published:2023-07-24 Issue:8 Volume:23 Page:689-692
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Sharma Ashish¹,Kumar Nilesh²,Parachuri Nikulaa³,Loewenstein Anat⁴,Bandello Francesco⁵,Kuppermann Baruch D⁶

Affiliation:

1. Lotus Eye Hospital and Institute, Coimbatore, TN, India

2. Madhavi Netralaya, Ara, Bihar, India

3. Department of Vitreoretina, Sankara Eye Hospital, Coimbatore, TN, India

4. Division of Ophthalmology, Tel Aviv Medical, Tel Aviv University, Israel

5. Scientific Institute San Raffaele, University Vita-Salute, Milano, Italy

6. Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2239706

Reference25 articles.

1. Research S Anti-VEGF market size is projected to reach USD 13.54 Billion by 2030, growing at a CAGR of 1.02%: straits research. GlobeNewswire News Room. 2022. [cited May 2, 2023]. Available at: https://www.globenewswire.com/news-release/2022/07/21/2484044/0/en/Anti-VEGF-Market-Size-is-projected-to-reach-USD-13-54-Billion-by-2030-growing-at-a-CAGR-of-1-02-Straits-Research.html

3. Anon. FDA approves samsung bioepis and biogen’s BYOOVIZTM (SB11), LUCENTIS® biosimilar (ranibizumab-nuna) | Biogen. [cited Sep 29, 2022]. Available at: https://investors.biogen.com/news-releases/news-release-details/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11

4. Approved biosimilar ranibizumab—a global update

5. Ophthalmic biosimilars: Lessons from India

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparing for the third decade of biosimilars;Expert Opinion on Biological Therapy;2023-08-03